An update of consensus guidelines for warfarin reversal

Area of Science:

• Pharmacology
• Clinical Medicine
• Cardiology

Background:

• Warfarin is the most prescribed anticoagulant in Australia and New Zealand despite bleeding risks.
• Its use is expected to continue for specific indications and patient groups.
• Effective management strategies are crucial for safe warfarin therapy.

Purpose of the Study:

• To outline strategies for managing over-warfarinisation and warfarin use during invasive procedures.
• To provide guidance on target international normalised ratio (INR) levels for various indications.
• To detail the use of reversal agents and perioperative management.

Main Methods:

• Review of current guidelines and clinical practices for warfarin management.
• Analysis of risk factors for bleeding and thrombosis associated with warfarin.
• Evaluation of reversal agents including Vitamin K1, Prothrombinex-VF, and fresh frozen plasma (FFP).

Main Results:

• Target INR ranges from 2.0-3.0 for most indications, and 2.5-3.5 for specific valve conditions.
• Withholding warfarin with monitoring is safe for elevated INR (4.5-10.0) without bleeding.
• Prothrombin complex concentrates (PCC) are preferred for immediate reversal over FFP, with Vitamin K1 essential for sustained effect.
• Surgery can proceed with minimal risk if INR ≤ 1.5; warfarin may not require interruption for low-risk procedures.

Conclusions:

• Comprehensive strategies for managing warfarin, including target INR and reversal agents, can mitigate bleeding risks.
• Prothrombinex-VF and Vitamin K1 are key components of warfarin reversal in Australia and New Zealand.
• Careful perioperative assessment balancing thrombosis and bleeding risks is essential for patients on warfarin.